论文部分内容阅读
目的探讨乳腺癌新辅助化疗与雌激素受体(ER)、孕激素受体(PR)阳性表达率的相关性;乳腺癌新辅助化疗效果与ER、PR阳性表达的关系。方法将128例乳腺癌患者分为新辅助化疗组(54例)和对照组(74例),对2组患者ER、PR的检测结果进行对比分析,并进行统计学处理;对新辅助化疗组术前肿块的变化进行疗效评价,并与术后ER、PR阳性表达结果进行对比分析。结果新辅助化疗组ER阳性表达31例(占57.41%),PR阳性表达26例(占48.15%),对照组ER阳性表达38例(占51.35%),PR阳性表达35例(47.30%)。2组间ER、PR阳性率比较无显著性差异(P>0.05)。ER、PR阳性表达强度越高,则新辅助化疗效果越好。结论乳腺癌新辅助化疗与ER、PR阳性表达率无相关性,而其疗效与ER、PR阳性表达强度呈正相关。
Objective To investigate the correlation between the neoadjuvant chemotherapy and estrogen receptor (ER) and progesterone receptor (PR) positive rate in breast cancer and the relationship between neoadjuvant chemotherapy and the expression of ER and PR in breast cancer. Methods 128 patients with breast cancer were divided into neoadjuvant chemotherapy group (n = 54) and control group (n = 74). The results of ER and PR were compared between the two groups and statistically analyzed. The neoadjuvant chemotherapy group Preoperative tumor changes were evaluated, and with postoperative ER, PR positive expression results were analyzed. Results The positive expression of ER in the neoadjuvant chemotherapy group was 31 cases (57.41%), PR was 26 (48.15%) in the neoadjuvant chemotherapy group, 38 cases (51.35%) were positive in the control group, and 35 cases (47.30%) were positive in PR. There was no significant difference in the positive rates of ER and PR between the two groups (P> 0.05). The higher the positive expression intensity of ER and PR, the better the effect of neoadjuvant chemotherapy. Conclusion There is no correlation between the neoadjuvant chemotherapy and the positive expression rate of ER and PR in breast cancer, but the curative effect is positively correlated with the positive expression intensity of ER and PR.